Zhongmin Maxwell Wang

机构：Hebei Medical University, China National Pharmaceutical Group Corporation (China), Tangshan People's Hospital, Fourth Hospital of Hebei Medical University · ORCID：0000-0002-1683-5147

发表论文 59 篇 · 总被引 1741 次 · h-index 19

代表论文

• Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant (2024 · JAMA · 被引 187)
• Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China (2025 · The Lancet · 被引 154)
• First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial (2025 · Nature Medicine · 被引 90)
• Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial (2024 · Nature Medicine · 被引 45)
• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 33)
• Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study (2024 · Signal Transduction and Targeted Therapy · 被引 19)